GSK's acquisition of Ozureprubart and DBV's successful Phase 3 trial for Viaskin Peanut reshape the allergy treatment market.
Major M&A Deals Highlight the Future Value of Allergy Immunotherapy
Global pharmaceutical companies are making significant inroads into the allergy treatment market, leading to a rapidly changing landscape. GlaxoSmithKline (GSK) acquired RAPT Therapeutics for $2.2 billion in March of this year, securing Ozureprubart, a long-acting anti-IgE monoclonal antibody (mAb). Novartis also agreed to acquire Excellergy for up to $2 billion, adding the next-generation anti-IgE ECRI candidate, Exl-111, to its portfolio. These major deals demonstrate a paradigm shift from traditional symptomatic relief to disease-modifying therapies that reprogram the patient's immune system. Global pharmaceutical companies are demonstrating the long-term value of this market, which is expected to grow from $1.8 billion in 2023 to $4.9 billion in 2033, with substantial capital investment.
Successful Completion of Phase 3 Trials and Advancement of Innovative Platforms Towards New Drug Approval
Concrete clinical results are emerging in the field of peanut allergy treatment for infants and young children. In December of last year, French company DBV Technologies recorded a response rate of 46.6% in its Phase 3 clinical trial of Viaskin Peanut patch for pediatric patients, demonstrating overwhelming significance compared to the placebo group (14.8%). With a financial capacity of $309 million, they are planning to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) within the first half of this year. Meanwhile, Australian company Aravax has completed enrollment in its Phase 2 clinical trial of PVX108, a peptide therapy that retrains the immune system without using peanut protein, and is expected to announce top-line results in the first half of this year. The advancement of these platforms, which have a low risk of anaphylaxis, will significantly improve patient convenience.
Diversified Antibody and Platform Fusion for Maximizing Immune Modulation
Sophisticated antibody technologies are also attracting attention for their ability to control allergic immune responses at the source. Swiss company Mabylon initiated Phase 1a/1b clinical trials of its trispecific monoclonal antibody MY006 in December of last year, exploring a new preventive therapy for peanut allergies. IgGenix has completed patient enrollment and dosing in its Phase 1 clinical trial of IGNX001, a high-affinity IgG4 monoclonal antibody isolated from patient blood, and is awaiting the results. In addition, Inimmune is scheduled to announce top-line data from its Phase 2 clinical trial of INI-2004, a TLR4 agonist for allergic rhinitis, in June of this year. They are also conducting pre-clinical studies in combination with Intrommune's oral mucosal immunotherapy (OMIT) platform, MultiFood INT302 toothpaste, to maximize immune induction efficiency.
Portfolio Diversification and Global Expansion Strategies of Existing Market Leaders
Stallergenes Greer, a leading company in allergy immunotherapy, possesses a unique product line including Staloral and Oralair tablets, Actair, and Palforzia for peanut allergy treatment. They are not limited to Western markets and signed an exclusive partnership agreement with Chinese company Nuance Pharma in September of last year for the clinical development and approval of Actair in China. This is a strategic move to secure a foothold in the Asia-Pacific (APAC) region, where the number of allergy patients is rapidly increasing, and to secure additional growth momentum. The combination of proven global distribution networks and innovative platforms is considered the most ideal business success model, from initial investment attraction to final commercialization.
With the global allergy immunotherapy market expected to grow to $4.9 billion by 2033, GSK's acquisition of Ozureprubart (Phase 2b) and Novartis's acquisition of Exl-111 (Phase 1) demonstrate that the R&D focus of major pharmaceutical companies has completely shifted from simple symptom relief to disease-modifying therapies. In the short term, DBV Technologies' Biologics License Application (BLA) for the Viaskin Peanut patch, expected in the first half of this year, and Aravax's top-line results from its Phase 2 clinical trial of T-cell targeted therapy PVX108 will determine the short-term momentum of the market. In the medium to long term, biotech companies with innovative technology platforms such as trispecific antibody MY006 and high-affinity IgG4 antibody IGNX001 are expected to replace existing standard treatments such as Xolair and drive additional M&A deals with major pharmaceutical companies. Therefore, industry professionals and researchers should pay attention to the clinical progress of adjuvant fusion technologies such as TLR4 agonist INI-2004, which is undergoing pre-clinical studies to confirm synergistic efficacy, and the ability to penetrate emerging markets such as Asia, as demonstrated by the licensing agreement with Nuance Pharma for Actair in China, will be a key differentiator.
Source: Labiotech (rss)